NCT01137955View on ClinicalTrials.gov

Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Celiac Disease
Interventions
DRUG

Rifaximin

Rifaximin 400mg orally three times a day for 10 days total

DRUG

Placebo

Placebo orally three times a day for 10 days total

Trial Locations (1)

10032

Celiac Disease Center at Columbia University, New York

All Listed Sponsors
collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

Columbia University

OTHER

NCT01137955 - Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease | Biotech Hunter | Biotech Hunter